Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY573636 in platinum-resistant ovarian cancer
2006-005971-17Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tasisulam in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started May 2007; status: completed.
02
Drugs
tasisulam
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2006-005971-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005971-17.